Ney Carter Borges: The Central Role of Endothelial Dysfunction in Cardiovascular Disease Progression
Ney Carter Borges, Member Cardiologist of Global Physician Association at Cleveland Clinic Florida, shared on LinkedIn:
“The Central Role of Endothelial Dysfunction in Cardiovascular Disease Progression
The vascular endothelium is a highly specialized, metabolically active organ that plays a pivotal role in cardiovascular homeostasis. It regulates vascular tone, platelet activity, leukocyte adhesion, oxidative balance, and thrombosis primarily through the synthesis of vasoactive mediators, notably nitric oxide (NO). In healthy individuals, endothelial cells maintain high NO bioavailability, which promotes vasodilation, inhibits smooth muscle proliferation, suppresses inflammation, and prevents platelet aggregation.
Epidemiological and mechanistic studies consistently demonstrate that endothelial dysfunction precedes overt atherosclerosis by decades. Flow-mediated dilation (FMD), a validated marker of endothelial function, declines progressively with age—approximately 0.5–1.0% per decade in low-risk populations—and is markedly impaired in individuals with traditional cardiovascular risk factors. Large cohort studies show that a 1% reduction in FMD is associated with an 8–13% increase in future cardiovascular events.
Reduced NO bioavailability is a hallmark of endothelial dysfunction and is strongly linked to atherosclerotic progression. Experimental and clinical data indicate that NO production may decline by 40–60% in middle-aged adults with metabolic syndrome or diabetes, accelerating lipid oxidation, vascular inflammation, and plaque formation. In advanced stages, severe NO depletion (<20% of physiological levels) is associated with arterial stiffening, plaque instability, and a significantly increased risk of thrombotic events.
Clinically, endothelial dysfunction independently predicts myocardial infarction, stroke, and cardiovascular mortality, even after adjustment for conventional risk factors. Meta-analyses involving over 20,000 patients demonstrate that impaired endothelial function confers a 1.7–2.3-fold higher risk of major adverse cardiovascular events. These findings underscore that endothelial health is not merely a marker but a central driver of cardiovascular disease complexity, progression, and clinical outcomes—making it a critical therapeutic target in modern preventive cardiology.”

More posts featuring Ney Carter Borges.
-
Aug 15, 2026, 18:03Alejandro González Veliz: Pulmonary Embolism Is Not Always an Anticoagulation-Only Problem
-
Aug 15, 2026, 17:57Ayesha Zia: A New Foundation for Pediatric Pulmonary Embolism Research and Care
-
Aug 15, 2026, 17:50Muhammad Shaheer Bin Faheem: 25 Years of Thromboembolism and Hypertension Mortality
-
Aug 15, 2026, 17:21Bilal Salman։ NETosis as a Therapeutic Target in Inflammation and Thrombosis
-
Aug 15, 2026, 16:58Andrew Jackson: Oral Anticoagulants for the Prophylaxis of Catheter-Related Thrombosis
-
Aug 15, 2026, 16:52Understanding Blood Clots During Pregnancy and After Birth – Thrombosis UK
-
Aug 15, 2026, 16:39Liri Seraj: How Summer Dehydration Affects Blood and Thrombosis Risk
-
Aug 15, 2026, 16:29Denise Rezende: What Should Clinicians Do When Thrombosis Occurs Despite DOAC Therapy?
-
Aug 15, 2026, 16:20Anoop Singh: When India Became the Key to a Faster Hemophilia A Trial